Founded in 1997, Ergomed plc is a profitable UK-based company, dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs. It operates globally in over 40 countries.

Ergomed plc has two complementary businesses:
(1) The Services Business – a well-established, clinical research business providing services to the pharmaceutical and biotechnology industry; and
(2) The Co-Development Business – a growing portfolio of partnerships with pharmaceutical and biotech companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including outlicensing milestones as well as sales of the product

Since its formation, Ergomed plc has been providing expertise in clinical development / trial management from the largest pharmaceutical companies, as well as many small and mid-sized drug development companies. Ergomed plc successfully manages clinical development from Phase I through to late phase programmes.

Ergomed plc has a wide therapeutic focus, but has particular expertise in oncology, neurology and immunology and the development of orphan drugs. Ergomed plc believes its approach to clinical trials is differentiated from that of other providers by its innovative Study Site Management model and the use of Study Physician Teams, resulting in a close relationship between Ergomed plc and the investigational sites involved in clinical trials. As well as providing high quality clinical development services, Ergomed plc is building a portfolio of co-development partnerships with pharma and biotech companies which share the risks and rewards of drug development. Ergomed plc leverages its expertise and services in return for carried interest in the drugs under development.

The company has planned, managed, monitored, and reported clinical trials with a range of technologies that include small molecule drugs, monoclonal antibodies, tri-functional antibodies, soluble receptors and other targeted agents, cancer vaccines and immunotherapy, radioactive agents, and photodynamic therapies.

http://www.ergomedplc.com/

12:20 23/10/2017
Broker Forecast - Numis issues a broker note on Ergomed Plc
Numis today reaffirms its buy investment rating on Ergomed Plc (LON:ERGO) and raised its price target to 300p (from 280p). Story provided by StockMarketWire.com